Asia Healthcare Blog
Exploring the intersection of investment and development, in Asia



China, HK, Macau

November 4, 2011

Investment in China’s Healthcare Space “Soars”

IMG_1312

          While grabbing breakfast this morning in Beijing I happened across the following headline from the always humorous (although not always intentionally so) China Daily:  “Medical and Healthcare Investment Soars”.  According to the paper, 2011 is on pace to set a new record for inbound investment in China’s healthcare space.  Through August, investment has reached $3.5 billion, or “2.7 times more than the total amount over the whole of 2010.”  It’s actually more than the last four years combined (2007-2010 totaled out at $3.156bn versus the YTD total of $3.524bn).

Released as part of last week’s China Bio & Healthcare Industry Investment Forum 2011 here in Beijing, the report noted “132 investments in 2010, more than double the 60 registered in 2009.”  Other than the underlying desperate need for new healthcare services and products delivered to Chinese consumers, what is driving this massive inflow of capital is that “more people are now included in China’s medical insurance system.”

Almost across the board – whether talking to specialists in China’s medical device, pharma, private hospital or eldercare market niches – the role of the government as it increases payment to healthcare providers is one of the single most important inflection points which will determine the attractiveness of investing in China’s healthcare market.

Pay attention to companies like Blackstone, IDG Capital Partners and Sequoia Capital who have already made major investments in China in these areas.  If they continue to increase their investment portfolio in China for the healthcare space, it is a signal that the time is right for healthcare investors in China to make similar moves of their own.  IDG alone has 12 investments in China’s medical space, a portion of which you can see here.



About the Author

Benjamin
Ben is the Founder and Managing Director of Rubicon Strategy Group, a consulting firm specializing in helping American and European companies enter emerging markets. He is a member of the National Committee on US-China Relations and holds an advisory board seat at Indiana University’s Research Center on Chinese Politics and Business. He is a columnist for the Asia Times on US-China trade and economic policy matters, with a particular focus on how relations between the two countries are being impacted post the 2008 financial crisis. As a founder of the consulting firm Teleos, he was an early advocate for Chinese companies moving away from cost-only business models towards ones that emphasized brand building, innovation and product development. He founded Teleos Healthcare which licensed, capitalized and commercialized the IP for an OTC medical appliance used to help stop nosebleeds. This company successfully partnered with a major US pharmaceutical company on the product launch for the hemophilia and VWD bleeding disorder community. In addition, Ben has successfully managed projects in China across a number of industries, ranging from consumer goods to more complex engineered products. He holds his MBA from Duke University in Durham, North Carolina.




2 Comments


  1. [...] post on the YTD trends of investments into China’s healthcare market.  Head over there and read the post for more on the numbers. Category: China, Healthcare Tag: China, China healthcare, Healthcare [...]


  2. [...] Investment in China’s Healthcare Space “Soars” http://bit.ly/rpmaiY [...]



Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>